Pasithea Therapeutics Corp. (KTTA)
KTTA moved a median of +0.05% 30 minutes after news, and -1.17% by the close. How KTTA actually reacts to news — the realized, point-in-time move the market made, measured across 194 labeled events over the last three years with zero look-ahead.
KTTA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 165 |
| 30-min | +0.05% | 52% | 171 |
| 60-min | +0.23% | 54% | 172 |
| to close | -1.17% | 43% | 189 |
| Middle 50% of KTTA reactions | -2.61% to +2.66% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 194 |
Half of all Pasithea Therapeutics Corp. news events land between -2.61% and +2.66% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when KTTA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KTTA's baseline. Nothing else.
Recent KTTA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Pasithea Therapeutics For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +4.91% | +3.41% | |
| Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference | Press release | GlobeNewswire | +1.82% | -2.49% | |
| Form 8-K Pasithea Therapeutics For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | -5.20% | |
| Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences | Press release | GlobeNewswire | +1.63% | +0.07% | |
| Form 8-K Pasithea Therapeutics For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -4.74% | -3.48% | |
| Form 10-Q Pasithea Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.55% | -1.85% | |
| Form ARS Pasithea Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.84% | — | |
| Form DEF 14A Pasithea Therapeutics For: Sep 09 | SEC filing · Form DEF | SEC EDGAR | +1.84% | — | |
| Form PRE 14A Pasithea Therapeutics For: Jul 29 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -1.33% | |
| Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 | Press release | GlobeNewswire | +0.00% | -5.25% | |
| Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit | Press release | GlobeNewswire | +0.00% | -1.64% | |
| Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion | Press release | GlobeNewswire | -12.01% | -8.13% | |
| Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial | Press release | GlobeNewswire | -1.09% | -5.73% | |
| Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference | Press release | GlobeNewswire | +0.33% | -2.95% | |
| Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) | Press release | GlobeNewswire | +0.62% | -5.15% | |
| Form 10-Q Pasithea Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.51% | +0.00% | |
| Form 8-K Pasithea Therapeutics For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +2.74% | -2.86% | |
| Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer | Press release | GlobeNewswire | +2.37% | +0.77% | |
| Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) | Press release | GlobeNewswire | -2.09% | -4.49% | |
| Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity | Press release | GlobeNewswire | -13.48% | +3.49% | |
| Form 10-K Pasithea Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.70% | +4.48% | |
| Form 8-K Pasithea Therapeutics For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | -0.85% | -4.18% | |
| Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.00% | -0.86% | |
| Form S-8 Pasithea Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -0.56% | |
| Form 8-K Pasithea Therapeutics For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | +0.62% | |
| Form EFFECT Pasithea Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +0.83% | +1.54% | |
| Form POS AM Pasithea Therapeutics | SEC filing · Form POS | SEC EDGAR | +0.03% | -1.25% | |
| Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines | Press release | GlobeNewswire | +1.66% | -0.27% | |
| Form DEF 14A Pasithea Therapeutics For: Jan 28 | SEC filing · Form DEF | SEC EDGAR | -0.22% | +0.00% | |
| Form PRE 14A Pasithea Therapeutics For: Jan 28 | SEC filing · Form PRE | SEC EDGAR | +1.77% | +4.42% | |
| Form 8-K Pasithea Therapeutics For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.57% | |
| Form 8-K Pasithea Therapeutics For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.48% | |
| Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock | Press release | GlobeNewswire | +0.00% | +3.48% | |
| Form EFFECT Pasithea Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -3.57% | -7.94% | |
| Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock | Press release | GlobeNewswire | +27.59% | +1.38% | |
| Form S-1/A Pasithea Therapeutics | SEC filing · Form S-1 | SEC EDGAR | +27.59% | +1.38% | |
| Form 8-K Pasithea Therapeutics For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +8.47% | +107.84% | |
| Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS | Press release | GlobeNewswire | -6.63% | +18.72% | |
| Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data | Press release | GlobeNewswire | -14.82% | -1.92% | |
| Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients | Press release | GlobeNewswire | -3.23% | -12.29% | |
| Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study | Press release | GlobeNewswire | -7.87% | -18.40% | |
| Form S-1 Pasithea Therapeutics | SEC filing · Form S-1 | SEC EDGAR | -1.85% | -4.84% | |
| Form 8-K Pasithea Therapeutics For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -4.26% | -5.77% | |
| Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | Press release | GlobeNewswire | -4.26% | -5.77% | |
| Form 8-K Pasithea Therapeutics For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +4.64% | |
| Form 8-K Pasithea Therapeutics For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.24% | +0.61% | |
| Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | Press release | GlobeNewswire | +0.24% | +0.61% | |
| Form S-8 Pasithea Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -2.59% | +2.26% | |
| Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | Press release | GlobeNewswire | +2.15% | -2.49% | |
| Form 8-K Pasithea Therapeutics For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +2.01% | -1.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KTTA section they belong to.
Where else KTTA is measured.
KTTA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Pasithea Therapeutics Corp.'s median reaction calculated?
Every labeled KTTA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 194 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of KTTA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KTTA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.